{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:38:17Z","timestamp":1787164697124,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010571","name":"BMBF Berlin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010571","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.eclinm.2023.102237","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T04:43:54Z","timestamp":1696394634000},"page":"102237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5193-7755","authenticated-orcid":false,"given":"Gernot","family":"Rohde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Stenglein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9715-3449","authenticated-orcid":false,"given":"Hans","family":"Prozesky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Manudhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Sandulescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Overend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Neuschwander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Planz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Witzenrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2023.102237_bib1","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/jac\/dkaa564","article-title":"Evolution of practices regarding COVID-19 treatment in France during the first wave: results from three cross-sectional surveys (March to June 2020)","volume":"76","author":"Rolland","year":"2021","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.eclinm.2023.102237_bib2","article-title":"A\u00a0first draft of the history of treating coronavirus disease 2019: use of repurposed medications in United States hospitals","volume":"8","author":"Clancy","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.eclinm.2023.102237_bib3","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A\u00a0trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2023.102237_bib4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00018-021-04085-1","article-title":"The MEK1\/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine\/chemokine responses","volume":"79","author":"Schreiber","year":"2022","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.eclinm.2023.102237_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.antiviral.2011.05.009","article-title":"Inhibition of influenza virus-induced NF-kappaB and Raf\/MEK\/ERK activation can reduce both virus titers and cytokine expression simultaneously in\u00a0vitro and in\u00a0vivo","volume":"92","author":"Pinto","year":"2011","journal-title":"Antiviral Res"},{"key":"10.1016\/j.eclinm.2023.102237_bib6","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3389\/fimmu.2020.01446","article-title":"The COVID-19 cytokine storm; what we know so far","volume":"11","author":"Ragab","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.eclinm.2023.102237_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.570993","article-title":"Controlling cytokine storm is vital in COVID-19","volume":"11","author":"Tang","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.eclinm.2023.102237_bib8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/35060098","article-title":"Influenza virus propagation is impaired by inhibition of the Raf\/MEK\/ERK signalling cascade","volume":"3","author":"Pleschka","year":"2001","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.eclinm.2023.102237_bib9","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1515\/BC.2008.145","article-title":"RNA viruses and the mitogenic Raf\/MEK\/ERK signal transduction cascade","volume":"389","author":"Pleschka","year":"2008","journal-title":"Biol Chem"},{"key":"10.1016\/j.eclinm.2023.102237_bib10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.antiviral.2017.03.024","article-title":"The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in\u00a0vitro and provides a prolonged treatment window compared to standard of care in\u00a0vivo","volume":"142","author":"Haasbach","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.eclinm.2023.102237_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104806","article-title":"Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model","volume":"178","author":"Laure","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.eclinm.2023.102237_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.611958","article-title":"Improved in\u00a0vitro efficacy of baloxavir marboxil against influenza A virus infection by combination treatment with the MEK inhibitor ATR-002","volume":"12","author":"Hamza","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.eclinm.2023.102237_bib15","article-title":"Risk stratification of patients admitted to hospital with COVID-19 using the ISARIC WHO clinical characterisation protocol: development and validation of the 4C Mortality Score","volume":"370","author":"Knight","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2023.102237_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0265233","article-title":"Visualizing omicron: COVID-19 deaths vs. cases over time","volume":"17","author":"Arnaout","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.eclinm.2023.102237_bib17","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/s41591-022-01887-z","article-title":"Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1\/BA.1.1 or BA.2 subvariant infection in Southern California","volume":"28","author":"Lewnard","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2023.102237_bib18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41577-022-00720-5","article-title":"Estimating disease severity of Omicron and Delta SARS-CoV-2 infections","volume":"22","author":"Sigal","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.eclinm.2023.102237_bib19","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2023.102237_bib20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.8890","article-title":"Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis","volume":"2","author":"Mincu","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eclinm.2023.102237_bib21","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/CMR.0000000000000599","article-title":"Inflammatory side effects of BRAF and MEK inhibitors","volume":"29","author":"Mackin","year":"2019","journal-title":"Melanoma Res"},{"key":"10.1016\/j.eclinm.2023.102237_bib22","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/eye.2015.82","article-title":"MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity","volume":"29","author":"Duncan","year":"2015","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.eclinm.2023.102237_bib23","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/IAE.0000000000002451","article-title":"Ocular adverse events associated with MEK inhibitors","volume":"39","author":"M\u00e9ndez-Mart\u00ednez","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.eclinm.2023.102237_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00224-20","article-title":"Understanding the impact of resistance to influenza antivirals","volume":"34","author":"Holmes","year":"2021","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.eclinm.2023.102237_bib25","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1021\/acs.chemrev.0c00648","article-title":"Drug design strategies to avoid resistance in direct-acting antivirals and beyond","volume":"121","author":"Matthew","year":"2021","journal-title":"Chem Rev"},{"key":"10.1016\/j.eclinm.2023.102237_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.antiviral.2018.07.020","article-title":"Comparison of antiviral resistance across acute and chronic viral infections","volume":"158","author":"Mason","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.eclinm.2023.102237_bib27","series-title":"FDA updates sotrovimab emergency use authorization","year":"2022"},{"key":"10.1016\/j.eclinm.2023.102237_bib28","series-title":"FDA announces bebtelovimab is not currently authorized in any US region","year":"2022"},{"key":"10.1016\/j.eclinm.2023.102237_bib29","article-title":"A\u00a0living WHO guideline on drugs for Covid-19","volume":"370","author":"Agarwal","year":"2020","journal-title":"BMJ"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023004145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023004145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:22:21Z","timestamp":1762899741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537023004145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":27,"alternative-id":["S2589537023004145"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102237","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.102237","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Atriva Therapeutics GmbH, Martinsried, Germany. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102237"}}